CSL Outgoing CEO Deposed By Lawyers In U.S. Plasma Price-Fixing Suit
This article was originally published in PharmAsia News
CSL's outgoing CEO Brian McNamee has been deposed by attorneys in a U.S. class-action suit against the Australian government's vaccine maker allegedly involved in international price-fixing of blood plasma.
You may also be interested in...
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.